24-Dec-2025
Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference
Business Wire (Thu, 18-Dec 8:00 AM ET)
Business Wire (Fri, 12-Dec 1:15 PM ET)
Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research
Business Wire (Thu, 4-Dec 8:00 AM ET)
Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm
Globe Newswire (Wed, 3-Dec 9:19 AM ET)
Twist Bioscience Highlights Robust Growth and Innovation in Fiscal 2025 Results
Market Chameleon (Fri, 14-Nov 3:18 AM ET)
Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results
Business Wire (Fri, 14-Nov 7:15 AM ET)
Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference
Business Wire (Tue, 4-Nov 8:00 AM ET)
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Mon, 3-Nov 8:00 AM ET)
Business Wire (Thu, 23-Oct 8:00 AM ET)
Business Wire (Mon, 6-Oct 8:00 AM ET)
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Twist Bioscience trades on the NASDAQ stock market under the symbol TWST.
As of December 24, 2025, TWST stock price declined to $33.58 with 335,048 million shares trading.
TWST has a beta of 1.32, meaning it tends to be more sensitive to market movements. TWST has a correlation of 0.13 to the broad based SPY ETF.
TWST has a market cap of $2.05 billion. This is considered a Mid Cap stock.
Last quarter Twist Bioscience reported $99 million in Revenue and -$.45 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.01.
In the last 3 years, TWST traded as high as $60.90 and as low as $11.46.
The top ETF exchange traded funds that TWST belongs to (by Net Assets): ARKK, ARKG, XBI, VTI, IWM.
TWST has underperformed the market in the last year with a return of -30.2%, while SPY returned +17.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TWST shares. However, TWST has outperformed the market in the last 3 month and 2 week periods, returning +21.5% and +6.3%, while SPY returned +4.4% and +1.4%, respectively. This indicates TWST has been having a stronger performance recently.
TWST support price is $32.57 and resistance is $35.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TWST shares will trade within this expected range on the day.